Earlier this month, our team had the pleasure of attending the CMO Summit 360 in Boston. This event brought together top-level medical executives and experts from the biotech industry to discuss the latest trends and innovations in clinical decision making, regulatory strategy, communications, business development, and more. Sano sponsored a table at the event, and was excited to chat with and learn from both attendees and speakers. In this blog, we outline three key themes that emerged throughout the event: understanding the patient, engaging patient advocacy groups (PAGs), and driving diversity in medical research.
If you’re struggling to enroll your trial, you’re not alone. It’s so difficult that nine out of ten trials require the original timeline to be doubled to meet enrollment goals – and when you add in a genetic component, it becomes even more challenging.
This webinar, hosted by Patrick Short of Sano Genetics and featuring Wayne Eskridge and Dr. Neeraj Mistry focussed on the non-invasive screening and genomics in NAFLD (Nonalcoholic fatty liver disease).
Patient retention remains one of the most persistent constraints in clinical trial execution. When a significant proportion of enrolled patients drop out before study completion, the downstream effects are substantial: extended timelines, inflated costs, and compromised data quality.
This webinar, hosted by Patrick Short, CEO of Sano Genetics, and featuring Lindsey Wahlstrom-Edwards, Partnerships Lead at Sano Genetics, focused on the challenges patient organisations face in supporting innovation while also keeping patient health information safe.
MASH (Metabolic dysfunction-associated steatohepatitis) is a chronic liver disease that has gained significant attention from the pharmaceutical industry and clinical societies in the last decade. In this webinar, Dimitar Tonev, a trained hepatologist and an expert in chronic liver diseases, chatted with Patrick Short, CEO of Sano Genetics, to provide insights into the challenges and opportunities in developing drugs for MASH.
This webinar was hosted by Paul Wicks and featured Sano CEO Patrick Short, Rakhi Rajani from Genomics England, and Julian Hastings Ward who chairs the participant panel for Genomics England.
This webinar, hosted by Patrick Short, CEO of Sano Genetics, and featuring Dr. Mark Kotter, CEO of bit.bio, focused on precision medicine in multiple sclerosis. The conversation ranged from stem cells and the effect they can have on neurodegenerative disease like multiple sclerosis to the future of synthetic biology.
This webinar, hosted by Sano Genetics and featuring representatives from Newcastle University, Congenica, UK CRC Tissue Directory and Co-ordination Centre and Sano Genetics, focussed on the topic of diversity in clinical trials. The speakers discussed how to promote diversity in research participation, the importance of patient engagement and involvement, and how to flag potential issues earlier in the research process.
This webinar was hosted by Sano Genetics' scientific advisor, Paul Wicks, and featured representatives from Genomics England as well as Sage Bionetworks. The discussion centered around experiences and insights on patient engagement in precision medicine research, including how patients can be more involved in this type of research, as well as how design systems can impact engagement.